Bhageria & Jajodia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 29-07-2024
- Paid Up Capital ₹ 5.00 M
as on 29-07-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.00 Cr
as on 29-07-2024
- Revenue -87.50%
(FY 2023)
- Profit -430.88%
(FY 2023)
- Ebitda -239.04%
(FY 2023)
- Net Worth 13062.42%
(FY 2023)
- Total Assets 16464.59%
(FY 2023)
About Bhageria & Jajodia Pharmaceuticals
The Corporate was formerly known as Bhageria & Jajodia Pharmaceuticals Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹15.00 Cr.
Rahul Bhageria, Vikas Bhageria, Vinay Matoliya, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100MH2008PTC178713
- Company No.
178713
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2008
- Date of AGM
09 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Bhageria & Jajodia Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Matoliya  | Director | 28-Jan-2022 | Current |
| Rahul Bhageria | Director | 09-Sep-2021 | Current |
| Vikas Bhageria | Director | 08-Sep-2015 | Current |
| Ashish Kejdiwal | Director | 18-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Bhageria & Jajodia Pharmaceuticals.
Bhageria & Jajodia Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 87.5% decrease. The company also saw a substantial fall in profitability, with a 430.88% decrease in profit. The company's net worth Soared by an impressive increase of 13062.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bhageria & Jajodia Pharmaceuticals?
In 2023, Bhageria & Jajodia Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bhageria Exim Private LimitedActive 4 years 5 monthsRahul Bhageria and Vikas Bhageria are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 12 Oct 2023 | ₹15.00 Cr | Open |
How Many Employees Work at Bhageria & Jajodia Pharmaceuticals?
Unlock and access historical data on people associated with Bhageria & Jajodia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bhageria & Jajodia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bhageria & Jajodia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
